111 results
IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis in Human Immunodeficiency Virus Infected Individuals
Induction therapy:
 • AmBd (0.7–1.0
IDSA Treatment Recommendations ... for Cryptococcal ... Meningoencephalitis #IDSA ... #Treatment #management ... #meningitis #cryptococcus
IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis - Induction, Consolidation and Maintenance Therapy

Table 2. Antifungal Treatment Recommendations
IDSA Treatment Recommendations ... for Cryptococcal ... and Maintenance Therapy ... Meningoencephalitis #IDSA ... #Treatment #management
IDSA Recommendations for empirical antimicrobial therapy for purulent meningitis based on patient age and specific predisposing
IDSA Recommendations ... antimicrobial therapy ... condition #IDSA ... #Pharmacology #Management
IDSA - Antimicrobial Therapy for Staphylococcal and Streptococcal Skin and Soft Tissue Infections
 • Impetigo (Staphylococcus
IDSA - Antimicrobial ... Therapy for Staphylococcal ... #Antibiotics #management ... #treatment #idsa
IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis in Transplant Recipients
Induction therapy:
 • liposomal AmB (3–4 mg/kg per
IDSA Treatment Recommendations ... for Cryptococcal ... Meningoencephalitis #IDSA ... #Treatment #management ... #meningitis #cryptococcus
Recommendations for specific antimicrobial therapy in bacterial meningitis based on isolated pathogen and susceptibility testing.

#IDSA #Meningitis
antimicrobial therapy ... #IDSA #Meningitis ... #Pharmacology #Management
Rare Invasive Yeasts - Species and Antifungal Therapy

Cryptococcus, 
Geotrichum, 
Kodamaea, 
(Pichia)ohmeri, 
Malassezia, 
Pseudozyma, 
Rhodotorula, 
Saccharomyces, 
Saprochaete
and Antifungal Therapy ... Cryptococcus ... Yeasts #Antifungal #Therapy ... #Management #Table
Perianal Crohn's Disease - IBD Algorithm

 • 5-40% w perianal fistula
 • ↑ risk if colonic
refractory to medical therapy ... Crohns #Disease #IBDAlgorithm ... gastroenterology #management
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
• Combination therapy ... fluoroquinolone #IDSA ... Treatment #Regimen #Management
Initiation of ART in HIV patients with Opportunistic Infections
 • Pulmonary TB and CD4 cell count
regardless of CD4 • Cryptococcal ... Antiretroviral #Therapy ... Opportunistic #Infections #management